BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Cascade Technologies Corp., (OTCBB: CSDT) announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) has received a grant under the Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the company’s SkinSpect system for the detection of melanoma and other skin cancers.
